AHA 2024: GLP-1R agonist associated with better clinical outcomes in heart failure and CKD
Real-world data on GLP-1R agonists’ safety in heart failure and CKD patients was investigated using the TriNetX Research ...
AHA 2024: semaglutide continues to impress in diabetic kidney disease
KOLs interviewed by GlobalData think that semaglutide can be a treatment option for non-diabetic CKD patients whose kidney ...
Exenatide, a GLP-1 analog, by IV during cardiac surgery did not reduce organ injury or death
A large-scale clinical trial found that intravenous infusion of exenatide, a glucagon-like peptide-1 (GLP-1) analog ...
Tirzepatide lowered risk of worsening heart failure and CVD death for obese adults
In the international SUMMIT trial, adults with heart failure preserved ejection fraction (HFpEF) and obesity taking ...